AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26100 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropupillogram (E.P.G.) test dose of stimulant
Number of subjects: 3
Study 31324209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 0
Study 31324209 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 31324209 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS-AR intervention (Inform, Remind, Involve, Support)
Number of subjects: 0
Study 28237426 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) with a second subretinal injection in the contralateral eye
Number of subjects: 7
Study 28237426 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI)
Number of subjects: 7
Study 25812482 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial Preventive Problem‐Solving Intervention
Number of subjects: 0
Study 25812482 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23936037 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine women's faces and voices
Number of subjects: 0
Study 23936037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic video clips of feminine and masculine faces and voices
Number of subjects: 0
Study 23936037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic video clips of feminine and masculine voices
Number of subjects: 0
Study 23936037 — intervention group
Group type: EXPERIMENTAL
Intervention: Female stimuli
Number of subjects: 0
Study 23936037 — intervention group
Group type: COMPARATOR
Intervention: Male stimuli
Number of subjects: 0
Study 21803971 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent intradialytic hypotension
Number of subjects: 1426
Study 21803971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower predialysis systolic BP
Number of subjects: 1426
Study 21803971 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher predialysis systolic BP
Number of subjects: 1426
Study 21803971 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hypotension
Number of subjects: 1426
Study 18431534 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted elimination diet
Number of subjects: 27
Study 18431534 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 27
Study 16479339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 139
Study 16479339 — intervention group
Group type: COMPARATOR
Intervention: Kugel hernioplasty
Number of subjects: 139
Study 15023571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 38
Study 15023571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11685187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube group (Group 1)
Number of subjects: 15
Study 11685187 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube group (Group 2)
Number of subjects: 15
Study 9456664 — intervention group
Group type: EXPERIMENTAL
Intervention: Orapette SalivaCard HIV‐1/HIV‐2 antibody test
Number of subjects: 615
Study 9456664 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni‐SAL/ImmunoComb II HIV 1 & 2 Saliva Test
Number of subjects: 615
Study 9456664 — intervention group
Group type: COMPARATOR
Intervention: Serum samples tested by ELISA (Ortho)
Number of subjects: 615
Study 7695268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of piperacillin-tazobactam (50 mg/kg piperacillin and 6.25 mg/kg tazobactam)
Number of subjects: 47
Study 7695268 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of piperacillin-tazobactam (100 mg/kg piperacillin and 12.5 mg/kg tazobactam)
Number of subjects: 47
Study 7695268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of piperacillin-tazobactam
Number of subjects: 47
Study 3321586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-prednisone (CsA-P)
Number of subjects: 224
Study 3321586 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine-prednisone-antilymphocyte globulin (AZA-P-ALG)
Number of subjects: 224
Study 29725975 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Familact®)
Number of subjects: 0
Study 29725975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary self-care management program
Number of subjects: 40
Study 23897021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g·d of PEG‐creatine
Number of subjects: 77
Study 23897021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.50 g·d of PEG‐creatine
Number of subjects: 77
Study 23897021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 23820229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute brimonidine (0.025%)
Number of subjects: 180
Study 23820229 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphazoline/pheniramine
Number of subjects: 180
Study 23820229 — intervention group
Group type: COMPARATOR
Intervention: Control (Systane Ultra)
Number of subjects: 180
Study 20092840 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile implantation without dilation (group 1)
Number of subjects: 100
Study 20092840 — intervention group
Group type: COMPARATOR
Intervention: Penile implantation with dilation (group 2)
Number of subjects: 100
Study 18762098 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 13
Study 18762098 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 13
Study 15985272 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased bilateral temporal lobe gyrification index in preterm children
Number of subjects: 73
Study 15985272 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal gyrification index in preterm children
Number of subjects: 73
Study 15985272 — intervention group
Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 73
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 12499329 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27
Study 10660004 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of individual patient counseling
Number of subjects: 107
Study 10660004 — intervention group
Group type: EXPERIMENTAL
Intervention: Two telephone contacts
Number of subjects: 107
Study 10660004 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107
Study 10660004 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mEq supplemental oral potassium daily
Number of subjects: 107
Study 10660004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 8646351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal kanamycin (500 mg)
Number of subjects: 69
Study 8646351 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 69
Study 1353642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity factor VIII concentrate
Number of subjects: 33
Study 1353642 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-purity factor VIII concentrate
Number of subjects: 33
Study 1353642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 6650492 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP and intravenous fluids
Number of subjects: 8
Study 6650492 — intervention group
Group type: COMPARATOR
Intervention: Placebo and intravenous fluids
Number of subjects: 8
Study 6650492 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 8
Study 30846472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of peak oxygen consumption
Number of subjects: 14
Study 30846472 — intervention group
Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 14
Study 30846472 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) therapy
Number of subjects: 14
Study 29422023 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy delivered by trained and supervised lay health workers (6 sessions)
Number of subjects: 573
Study 29422023 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 573
Study 27533711 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 150
Study 27533711 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 150
Study 25266433 — intervention group
Group type: EXPERIMENTAL
Intervention: Poverty at birth
Number of subjects: 2853
Study 25266433 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education, pre‐ and postnatal growth in length, home stimulation
Number of subjects: 2853
Study 25266433 — intervention group
Group type: EXPERIMENTAL
Intervention: Home stimulation
Number of subjects: 2853
Study 25266433 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth in the first 2 years
Number of subjects: 2853
Study 22917555 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased monocyte count (≥800/μl)
Number of subjects: 3717
Study 19594194 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) - olanzapine, quetiapine, risperidone, ziprasidone
Number of subjects: 1770
Study 19594194 — intervention group
Group type: COMPARATOR
Intervention: First-generation antipsychotic (FGA) - perphenazine
Number of subjects: 1770
Study 19594194 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) in CUtLASS
Number of subjects: 1770
Study 17475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg on days 1 and 2, 40 mg on days 3 and 4, and 20 mg on days 5 and 6 (Group A)
Number of subjects: 100
Study 17475943 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 6 days (Group B)
Number of subjects: 100
Study 15940035 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 240
Study 15940035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 240
Study 15940035 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ganciclovir AUC
Number of subjects: 240
Study 15940035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic exposure to ganciclovir
Number of subjects: 240
Study 15940035 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ganciclovir exposure
Number of subjects: 240
Study 12500991 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (N)
Number of subjects: 6
Study 12500991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat supplemented diet (F)
Number of subjects: 6
Study 12500991 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (C)
Number of subjects: 6
Study 12500991 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted normal diet (AN)
Number of subjects: 6
Study 9583304 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 10 Hz for 5 minutes
Number of subjects: 7
Study 9583304 — intervention group
Group type: COMPARATOR
Intervention: Control period (no vibration)
Number of subjects: 7
Study 7712671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 16
Study 7712671 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 16
Study 2694509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of mefloquine/sulfadoxine/pyrimethamine (MSP)
Number of subjects: 914
Study 2694509 — intervention group
Group type: COMPARATOR
Intervention: Fansidar
Number of subjects: 914
Study 917333 — intervention group
Group type: EXPERIMENTAL
Intervention: Citiolone
Number of subjects: 0
Study 917333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 9 weeks (specifics not provided)
Number of subjects: 494
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ‐9 score at week 0
Number of subjects: 494
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation score at week 0
Number of subjects: 494
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ‐9 total score at week 9
Number of subjects: 494
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of side effects at week 9
Number of subjects: 494
Study 30851699 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ‐9 score defined as 10 or more at week 25
Number of subjects: 494
Study 29197871 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n=15)
Number of subjects: 72
Study 29197871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 72
Study 25271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (24 mg in 200 ml of water)
Number of subjects: 16
Study 25271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (72 mg in 200 ml of water)
Number of subjects: 16
Study 25271009 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 16
Study 23589672 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-7 (IL-7) administered to virally suppressed subjects
Number of subjects: 0
Study 21677070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 120
Study 21677070 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium mouthwash
Number of subjects: 120
Study 19552904 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, 3 times per day for 2 cycles)
Number of subjects: 37
Study 19552904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17926620 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of 2000 microg of VitB12
Number of subjects: 104
Study 17926620 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Carbamazepine
Number of subjects: 104
Study 15529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily)
Number of subjects: 40
Study 15529370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11574913 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day dose escalation of TMP-SMZ
Number of subjects: 100
Study 11574913 — intervention group
Group type: COMPARATOR
Intervention: Direct rechallenge of TMP-SMZ
Number of subjects: 100
Study 9623424 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty
Number of subjects: 30
Study 9623424 — intervention group
Group type: COMPARATOR
Intervention: Open gastroplasty
Number of subjects: 30
Study 7836551 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole 160/800 mg twice a day
Number of subjects: 8
Study 7836551 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 8
Study 3400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5% in oxygen
Number of subjects: 0
Study 3400846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 0
Study 3400846 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen
Number of subjects: 0
Study 30394153 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 obesity (BMI ≥ 40.0)
Number of subjects: 911
Study 30394153 — intervention group
Group type: COMPARATOR
Intervention: Overweight (BMI 25.0-29.9)
Number of subjects: 911
Study 30878303 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive transrectal biopsy with anterior sampling (median 19 cores)
Number of subjects: 340
Study 30878303 — intervention group
Group type: COMPARATOR
Intervention: Standard transrectal biopsy (median 12 cores)
Number of subjects: 340
Study 30878303 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive transrectal biopsy with anterior sampling
Number of subjects: 340
Study 30878303 — intervention group
Group type: EXPERIMENTAL
Intervention: Postbiopsy infections
Number of subjects: 340
Study 28380062 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (1700 mL infused)
Number of subjects: 115
Study 28380062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine 4% (1500 mL infused)
Number of subjects: 115
Study 28380062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 6% (1500 mL infused)
Number of subjects: 115
Study 28380062 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 5% (1500 mL infused)
Number of subjects: 115
Study 24980216 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral VA hypoplasia
Number of subjects: 28
Study 24980216 — intervention group
Group type: EXPERIMENTAL
Intervention: VA insufficiency
Number of subjects: 28
Study 24980216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 23454780 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual concept mapping method
Number of subjects: 80
Study 23454780 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face method (Control)
Number of subjects: 80
Study 21458598 — intervention group
Group type: COMPARATOR
Intervention: Low TFA diet (base diet, 34% energy from fat; 0.1% energy from TFA)
Number of subjects: 116
Study 21458598 — intervention group
Group type: EXPERIMENTAL
Intervention: Base diet with vaccenic acid (3.0% energy)
Number of subjects: 116
Study 21458598 — intervention group
Group type: EXPERIMENTAL
Intervention: Base diet with mixed isomers of TFA from partially hydrogenated vegetable oil (3.0% energy)
Number of subjects: 116
Study 21458598 — intervention group
Group type: EXPERIMENTAL
Intervention: Base diet with cis‐9, trans‐11 CLA (1.0% energy)
Number of subjects: 116
Study 19103321 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention
Number of subjects: 379
Study 19103321 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity intervention
Number of subjects: 379
Study 19103321 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 379
Study 17054617 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tutorial including the interactive 3-D model
Number of subjects: 28
Study 17054617 — intervention group
Group type: COMPARATOR
Intervention: Web-based tutorial without the interactive 3-D model (Control)
Number of subjects: 28
Study 12743981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-liposomal doxorubicin (Doxil™) at an initial dose of 55 mg/m2 every four weeks
Number of subjects: 47
Study 12743981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-liposomal doxorubicin (Doxil™)
Number of subjects: 47
Study 10893367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group underwent a lower-extremity training program, walking at 70% of maximum speed on the SWT, 1 hour, 6 days/week for 12 weeks.
Number of subjects: 60
Study 10893367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 60
Study 8882073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (250 micrograms) inhaled terbutaline
Number of subjects: 16
Study 8882073 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (1000 micrograms) inhaled terbutaline
Number of subjects: 16
Study 8882073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4 x 6 micrograms twice a day and as necessary, n = 19)
Number of subjects: 37
Study 1348219 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (4 x 100 micrograms twice a day and as necessary, n = 16)
Number of subjects: 37
Study 3987793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 0
Study 3987793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 0
Study 3987793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg 8 hourly
Number of subjects: 0
Study 3987793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg with Nifedipine 20 mg
Number of subjects: 0
Study 3987793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29768084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (780 nm, 25 J/cm2, 50 mW, 20 sec, and 1 J per point) on three points of the masseter and one point of the anterior temporal muscle on each side.
Number of subjects: 52
Study 29768084 — intervention group
Group type: COMPARATOR
Intervention: Sham group (device switched off, same procedure as laser group).
Number of subjects: 52
Study 27759409 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 31
Study 27759409 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 31
Study 27759409 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 31
Study 24725763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with atorvastatin (20mg/day) and ezetimibe (10mg/day)
Number of subjects: 0
Study 24725763 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with atorvastatin alone
Number of subjects: 0
Study 22340556 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate dressing and mouse epidermal growth factor (mEGF)
Number of subjects: 18
Study 22340556 — intervention group
Group type: EXPERIMENTAL
Intervention: mEGF
Number of subjects: 18
Study 22340556 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 20930431 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day) + alfacalcidol (0.25 µg/day)
Number of subjects: 40
Study 20930431 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (0.25 µg/day) alone
Number of subjects: 40
Study 18025881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Metabolic Syndrome (MS) defined by ATP-III criteria
Number of subjects: 881